GALE Stock Analysis: Galenica Sante | SW
Medical Distribution | SW, Switzerland | Market Cap: 4.447m CHF | 12M Return: 1.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.48M
Warnings
Tailwinds
Seasonality 9.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Galenica AG is a Swiss healthcare company headquartered in Bern, founded in 1927. It operates in two segments: Products & Care, which runs retail pharmacy chains (Amavita, Sun Store, and Coop Vitality) and the specialty pharmacy mediservice, and provides home medication, laboratory and diagnostic services, and consumer health products; and Logistics & IT, which offers pre-wholesale services such as storage, distribution, and debt collection to pharmaceutical manufacturers, along with master data systems, pharmacy management software, and scheduled delivery to pharmacies, drugstores, doctors, hospitals, and care homes.
As a company classified in the Health Care Distributors sub-industry, Galenica sits between pharmaceutical producers and end-points of care, combining B2B logistics with consumer-facing retail pharmacy operations. The Swiss pharmacy sector is subject to cantonal ownership and dispensing rules, which shape how pharmacy chains like Galenicas are structured and expanded.
- Pharmacy network expansion lifts Products & Care revenue
- Logistics & IT margins grow on healthcare digitization demand
- Swiss drug pricing regulation pressures pharmacy margins
| Net Income: 181.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.73 > 1.0 |
| NWC/Revenue: 3.31% < 20% (prev 7.64%; Δ -4.33% < -1%) |
| CFO/TA 0.09 > 3% & CFO 299.8m > Net Income 181.1m |
| Net Debt (1.19b) to EBITDA (347.1m): 3.43 < 3 |
| Current Ratio: 1.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago -0.10% < -2% |
| Gross Margin: 10.12% > 18% (prev 9.97%; Δ 0.15% > 0.5%) |
| Asset Turnover: 128.9% > 50% (prev 127.9%; Δ 1.03% > 0%) |
| Interest Coverage Ratio: 17.15 > 6 (EBIT TTM 230.7m / Interest Expense TTM 13.5m) |
| A: 0.04 (Total Current Assets 1.07b - Total Current Liabilities 932.9m) / Total Assets 3.34b |
| B: 0.45 (Retained Earnings 1.49b / Total Assets 3.34b) |
| C: 0.07 (EBIT TTM 230.7m / Avg Total Assets 3.21b) |
| D: 0.80 (Book Value of Equity 1.48b / Total Liabilities 1.86b) |
| Altman-Z'' = 3.04 = A |
| DSRI: 0.93 (Receivables 526.8m/539.0m, Revenue 4.14b/3.93b) |
| GMI: 0.99 (GM 9.97% / 10.12%) |
| AQI: 1.14 (AQ_t 0.58 / AQ_t-1 0.51) |
| SGI: 1.05 (Revenue 4.14b / 3.93b) |
| TATA: -0.04 (NI 181.1m - CFO 299.8m) / TA 3.34b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 21, 2026, the stock is trading at CHF 89.40 with a total of 52,961 shares traded. Over the past week, the price has changed by +2.23%, over one month by +6.11%, over three months by +0.48% and over the past year by +1.89%.
Current recommended Stop Loss: 87.50 (which is 2.1% or 1.4 ATR below the current price).
Galenica Sante has no consensus analysts rating.
P/E Trailing = 24.3852
P/E Forward = 20.79
P/S = 1.0726
P/B = 2.9335
Revenue TTM = 4.14b CHF
EBIT TTM = 230.7m CHF
EBITDA TTM = 347.1m CHF
Long Term Debt = 601.5m CHF (from longTermDebt, last quarter)
Short Term Debt = 326.0m CHF (from shortTermDebt, last quarter)
Debt = 1.30b CHF (from shortLongTermDebtTotal, last quarter) + Leases 244.0m
Net Debt = 1.19b CHF (calculated: Debt 1.30b - CCE 115.5m)
Enterprise Value = 5.64b CHF (4.45b + Debt 1.30b - CCE 115.5m)
Interest Coverage Ratio = 17.15 (Ebit TTM 230.7m / Interest Expense TTM 13.5m)
EV/FCF = 20.69x (Enterprise Value 5.64b / FCF TTM 272.4m)
FCF Yield = 4.83% (FCF TTM 272.4m / Enterprise Value 5.64b)
FCF Margin = 6.59% (FCF TTM 272.4m / Revenue TTM 4.14b)
Net Margin = 4.38% (Net Income TTM 181.1m / Revenue TTM 4.14b)
Gross Margin = 10.12% ((Revenue TTM 4.14b - Cost of Revenue TTM 3.72b) / Revenue TTM)
Gross Margin QoQ = 10.63% (prev 9.57%)
Tobins Q-Ratio = 1.69 (Enterprise Value 5.64b / Total Assets 3.34b)
Interest Expense / Debt = 1.03% (Interest Expense 13.5m / Debt 1.30b)
Taxrate = 17.31% (38.5m / 222.4m)
NOPAT = 190.8m (EBIT 230.7m * (1 - 17.31%))
Current Ratio = 1.15 (Total Current Assets 1.07b / Total Current Liabilities 932.9m)
Debt / Equity = 0.88 (Debt 1.30b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = 3.43 (Net Debt 1.19b / EBITDA 347.1m)
Debt / FCF = 4.37 (Net Debt 1.19b / FCF TTM 272.4m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.65% (Net Income 181.1m / Total Assets 3.34b)
RoE = 12.32% (Net Income TTM 181.1m / Total Stockholder Equity 1.47b)
RoCE = 11.14% (EBIT 230.7m / Capital Employed (Equity 1.47b + L.T.Debt 601.5m))
RoIC = 7.28% (NOPAT 190.8m / Invested Capital 2.62b)
WACC = 4.19% (E(4.45b)/V(5.75b) * Re(5.17%) + D(1.30b)/V(5.75b) * Rd(1.03%) * (1-Tc(0.17)))
Discount Rate = 5.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.37 | Cagr: 0.30%
[DCF] Terminal Value 77.97% ; FCFF base≈254.5m ; Y1≈291.7m ; Y5≈429.3m
[DCF] Fair Price = 105.8 (EV 6.46b - Net Debt 1.19b = Equity 5.27b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 78.36 | Revenue CAGR: 3.06% | SUE: 0.04 | # QB: 0
EPS current Year (2026-12-31): EPS=4.00 | Chg30d=+0.26% | Revisions=+50% | GrowthEPS=+6.3% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=4.27 | Chg30d=+0.24% | Revisions=+17% | GrowthEPS=+6.8% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +44% (up=5, down=1)